186 related articles for article (PubMed ID: 32999046)
21. Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4.
Prasmickaite L; Tenstad EM; Pettersen S; Jabeen S; Egeland EV; Nord S; Pandya A; Haugen MH; Kristensen VN; Børresen-Dale AL; ; Engebråten O; Maelandsmo GM
Mol Oncol; 2018 Sep; 12(9):1540-1558. PubMed ID: 29741811
[TBL] [Abstract][Full Text] [Related]
22. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
23. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
Pal SK; Moreira D; Won H; White SW; Duttagupta P; Lucia M; Jones J; Hsu J; Kortylewski M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013891
[TBL] [Abstract][Full Text] [Related]
24. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
25. Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.
Sun H; Wang C; Hu B; Gao X; Zou T; Luo Q; Chen M; Fu Y; Sheng Y; Zhang K; Zheng Y; Ren X; Yan S; Geng Y; Yang L; Dong Q; Qin L
Signal Transduct Target Ther; 2021 May; 6(1):187. PubMed ID: 34035222
[TBL] [Abstract][Full Text] [Related]
26. The Multifaceted S100A4 Protein in Cancer and Inflammation.
Ambartsumian N; Klingelhöfer J; Grigorian M
Methods Mol Biol; 2019; 1929():339-365. PubMed ID: 30710284
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
Zhang K; Yu M; Hao F; Dong A; Chen D
Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.
Rehman I; Goodarzi A; Cross SS; Leiblich A; Catto JW; Phillips JT; Hamdy FC
Prostate; 2007 Mar; 67(4):341-7. PubMed ID: 17219414
[TBL] [Abstract][Full Text] [Related]
29. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.
Gründker C; Bauerschmitz G; Schubert A; Emons G
Int J Oncol; 2016 Jun; 48(6):2713-21. PubMed ID: 27098123
[TBL] [Abstract][Full Text] [Related]
30. [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].
Chen XL; Wang LC; Zhang WG; Chen XY; Sun ZM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1254-8. PubMed ID: 18676277
[TBL] [Abstract][Full Text] [Related]
31. Oct-1 modifies S100A4 exchange between intra- and extracellular compartments in Namalwa cells and increases their sensitivity to glucocorticoids.
Dukhanina EA; Portseva TN; Pankratova EV; Soshnikova NV; Stepchenko AG; Dukhanin AS; Georgieva SG
Cell Cycle; 2016 Jun; 15(11):1471-8. PubMed ID: 27096393
[TBL] [Abstract][Full Text] [Related]
32. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors.
Grum-Schwensen B; Klingelhöfer J; Grigorian M; Almholt K; Nielsen BS; Lukanidin E; Ambartsumian N
Cancer Res; 2010 Feb; 70(3):936-47. PubMed ID: 20103644
[TBL] [Abstract][Full Text] [Related]
33. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
34. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Yang H; Zhao K; Yu Q; Wang X; Song Y; Li R
J Int Med Res; 2012; 40(2):475-85. PubMed ID: 22613408
[TBL] [Abstract][Full Text] [Related]
36. miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4.
He Z; Yu L; Luo S; Li M; Li J; Li Q; Sun Y; Wang C
BMC Cancer; 2017 Feb; 17(1):140. PubMed ID: 28209128
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody.
Hernández JL; Padilla L; Dakhel S; Coll T; Hervas R; Adan J; Masa M; Mitjans F; Martinez JM; Coma S; Rodríguez L; Noé V; Ciudad CJ; Blasco F; Messeguer R
PLoS One; 2013; 8(9):e72480. PubMed ID: 24023743
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
Burock S; Daum S; Keilholz U; Neumann K; Walther W; Stein U
BMC Cancer; 2018 Mar; 18(1):297. PubMed ID: 29544454
[TBL] [Abstract][Full Text] [Related]
39. S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence.
Mishra SK; Siddique HR; Saleem M
Cancer Metastasis Rev; 2012 Jun; 31(1-2):163-72. PubMed ID: 22109080
[TBL] [Abstract][Full Text] [Related]
40. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
